Amoxicillin/Clavulanate: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
ClaireLewis (talk | contribs) No edit summary |
||
(9 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: Amino-[[Penicillin]] | ||
*Dosage Forms: PO | *Dosage Forms: oral suspension, tablet, extended release tablet, chewable tablet | ||
*Common Trade Names: Augmentin | *Dosage Strengths: oral suspension: (125/31.25mg)/5mL, (200mg/28.5mg)/5mL, (250mg/62.5mg)/5mL, (400mg/57mg)/5mL, (600mg/42.9mg)/5mL; tablet: 250mg/125mg, 500mg/125mg, 875mg/125mg; extended release tablet: 1000mg/62.5mg; chewable tablet: 200mg/28.5mg, 400mg/57mg | ||
*Routes of Administration: PO | |||
*Common Trade Names: Augmentin, Augmentin XR, Augmentin ES-600 | |||
==Adult Dosing== | ==Adult Dosing== | ||
Infection, Bacterial | ===Infection, Bacterial=== | ||
*500mg- | *500mg-875mg PO q12h | ||
Pneumonia, community-acquired | ===[[Pneumonia]], community-acquired=== | ||
*2000mg ER PO q12h x 7-10 days | *2000mg ER PO q12h x 7-10 days | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Infection, Bacterial | ===Infection, Bacterial=== | ||
*25- | *25-45mg/kg PO divided q12h | ||
Otitis | ===[[Otitis media]]=== | ||
*90mg/kg/day PO divided q12h x 10 days | *90mg/kg/day PO divided q12h x 10 days | ||
==Special Populations== | ==Special Populations== | ||
*Pregnancy: B | *[[Drug pregnancy categories|Pregnancy risk]]: B | ||
*Lactation: probably safe | *Lactation: probably safe | ||
*Renal Dosing | *Renal Dosing | ||
Line 180: | Line 182: | ||
*[[Antibiotics (Main)]] | *[[Antibiotics (Main)]] | ||
== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:ID]] |
Revision as of 17:01, 19 September 2019
General
- Type: Amino-Penicillin
- Dosage Forms: oral suspension, tablet, extended release tablet, chewable tablet
- Dosage Strengths: oral suspension: (125/31.25mg)/5mL, (200mg/28.5mg)/5mL, (250mg/62.5mg)/5mL, (400mg/57mg)/5mL, (600mg/42.9mg)/5mL; tablet: 250mg/125mg, 500mg/125mg, 875mg/125mg; extended release tablet: 1000mg/62.5mg; chewable tablet: 200mg/28.5mg, 400mg/57mg
- Routes of Administration: PO
- Common Trade Names: Augmentin, Augmentin XR, Augmentin ES-600
Adult Dosing
Infection, Bacterial
- 500mg-875mg PO q12h
Pneumonia, community-acquired
- 2000mg ER PO q12h x 7-10 days
Pediatric Dosing
Infection, Bacterial
- 25-45mg/kg PO divided q12h
Otitis media
- 90mg/kg/day PO divided q12h x 10 days
Special Populations
- Pregnancy risk: B
- Lactation: probably safe
- Renal Dosing
- Adult: CrCl 10-30: give q12h, CrCl < 10, give q24h
- Pediatric: CrCl 10-30: give q12h, CrCl < 10, give q24h
- Hepatic Dosing
- Adult: none
- Pediatric: none
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- anaphylaxis
- steven johnson syndrome
- c.diff associated diarrhea
- hemolytic anemia
- leukopenia
- thrombocytopenia
- hepatitis
- seizures
Common
- diarrhea
- nausea
- rash
- pruritus
- vomiting
- glossitis
- transaminitis
Pharmacology
- Half-life: 1.1 hour
- Metabolism: Liver
- Excretion: urine
- Mechanism of Action:Bactericidal, inhibits cell wall mucopeptide synthesis, inhibits beta lactamases
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014